POST-CONGRESS WORKSHOP
Pharmacometric Tools for Maximally Precise Individualized Drug Therapy: Population PK/PD Modelling, Four types of Bayesian Adaptive Control, and Active "Dual" Control
Friday, October 9 & Saturday, October 10, 2009
This course is intended for physicians, pharmacists, clinical toxicologists and biomedical scientists with an interest in therapeutic drug monitoring, in population pharmacokinetic and pharmacodynamic modeling, and in optimal individualization of drug therapy for patient care. Prior experience in clinical pharmacokinetics will be an advantage. Participants will be introduced to the new MM-USC*PACK software, which will be compared with other approaches. This library of tools provides optimal approaches for clinical therapeutic drug monitoring as well as for nonparametric population PK/PD and physiological modeling.
Participants are encouraged to bring their laptop computers to the workshop, and to download and install, in the days prior to the workshop, the demonstration software from our web site (www.lapk.org, click on software), so they can do the hands-on parts of the workshop with us.
Faculty:
Dr. Roger Jelliffe, USC Laboratory of Applied Pharmacokinetics
Dr. Juergen Bulitta, Ordway Research Center, Albany, NY
Dr. George Drusano, Ordway Research Center, Albany, NY
Dr. Michael Neely, USC Laboratory of Applied Pharmacokinetics
Dr. Sander Vinks, University of Cincinnati
Objectives and Expectations:
After this workshop the participant should:
- Understand the General approach to Target-Oriented, Model Based, Individualized Drug Therapy;
- Understand the Clinical capabilities of Nonparametric Population Modeling;
- Understand the need for using assay standard deviation rather than CV% in reporting lab errors;
- Understand Multiple Model, maximally precise, Dosage Design;
- Understand the four types of Bayesian individualization of Pharmacokinetic Models, and when to use them;
- Become acquainted with models of bacterial growth and kill;
- Be acquainted with new approaches to optimize learning about the patient while treating him/her at the same time;
- Be aware of recent improved outcomes using Bayesian adaptive control;
- Apply these concepts to optimize practical therapy with Aminoglycosides, Vancomycin, Digoxin, HAART, and other drugs.
|
Day 1 - Friday, October 9
|
| |
|
| 0830 |
Registration
|
| 0900 |
Welcome
R. Jelliffe
|
| 0915 |
Review of Basic Pharmacokinetic behavior
S. Vinks
|
| 0930 |
TOOL #1 - Planning the Initial Regimen. Set a Specific Target, not a Range
R. Jelliffe
|
| 0950 |
TOOL #2 - Evaluating Renal Function
R. Jelliffe
|
| 0950 |
TOOL #3 - Describing assay errors by Standard Deviation, not CV%
R. Jelliffe
|
|
| 1030 |
Refreshment Break
|
|
| 1050 |
TOOL #4 - Estimating mostly timing errors (the remaining Environmental Noise)
R. Jelliffe
|
| 1100 |
TOOL #5 - Stating Dosage and Administration errors
R. Jelliffe
|
| 1115 |
TOOL #6 - Nonparametric Population models
• Why? – Properties, Capabilities
J. Bulitta
|
| 1145 |
TOOL #7 – Multiple Model (MM) Dosage Design
R. Jelliffe
|
|
| 1230 |
Lunch
|
|
| 1400 |
Monitoring the patient and the Regimen
• Linear, Nonlinear Regression
R. Jelliffe
|
| 1415 |
Bayes theorem
• Use population model
• State Dosage, assay, timing errors
R. Jelliffe
|
| 1430 |
TOOL #8 - Bayesian analysis
• MAP, MM, Hybrid, IMM
R. Jelliffe
|
|
| 1500 |
Refreshment Break
|
|
| 1520 |
Using IMM Bayesian in post surgical ICU patients
R. Jelliffe
|
| 1550 |
TOOL #9 - Adjusting the regimen
|
| 1600 |
Clinical Cases
• Plan a Gentamicin Regimen
• Monitor a Gent Patient
|
| 1620 |
TDM on a very unstable Tobramycin patient
|
| 1645 |
Outcomes with Individualized Therapy
S. Vinks
|
|
| 1715 |
Adjourn
|
|
Day 2 - Saturday, October 10
More Clinical Cases and Advanced Population Modeling
|
| |
|
| 0900 |
Clinical Cases - Digoxin Therapy
• Digoxin Effect correlates not with serum levels, but with Peripheral Compartment Concentrations – the Reuning Model
• Planning the Initial Regimen
• Stating serum concentration target goals
• Stating Peripheral Compartment target goals
• Patients with Atrial Fibrillation and Flutter
• The Falk Study in Patients with Atrial Fibrillation
• Two patients with Atrial Fibrillation
R. Jelliffe
|
| 0945 |
Concentration versus Time Dependent Drugs
|
| 1000 |
Vancomycin
• A q 12 h schedule
• A Continuous IV infusion schedule
|
|
| 1030 |
Refreshment Break
|
|
| 1050 |
Individualized Therapy of Children with HIV
M. Neely
|
| 1120 |
More 0n Population Modeling - Consistency, Stochastic Convergence, Efficiency, Precision
R. Jelliffe
|
| 1145 |
Making an NPAG population model of an Aminoglycoside
R. Jelliffe
|
|
| 1230 |
Lunch
|
|
| 1400 |
Making an Indirect Response Model
J. Bulitta
|
| 1430 |
Preventing emergence of bacterial resistance
G. Drusano
|
| 1500 |
Modeling Bacterial (or viral) Growth and Kill
S. Vinks
|
|
| 1530 |
Refreshment Break
|
|
| 1545 |
Planning the Gentamicin regimen again
• For a 20 yr old patient
• For a 65 yr old patient
|
| 1615 |
TOOL #10 - A New Tool for Learning about the Patient Optimally while Treating him/her at the same time - Optimal Active Dual Control
R. Jelliffe
|
| 1645 |
More Outcomes with Individualized Therapy
M. Neely
|
| 1710 |
Still more Outcomes with Individualized Therapy
R. Jelliffe
|
| 1730 |
Adjourn
|
IATDMCT 2009 Congress Secretariat
Email: congress@eventsmgt.com
4 Cataraqui Street, Suite 310
Kingston, ON K7K 1Z7
Tel: +1-613-531-8166 / Fax: +1-613-531-0626
|
11th International Congress of
